Hsa_circ_0101308 adjusted by N6-methyladenosine (m(6)A) impacts chemo-resistance in cervical cancer via sponging miR-224

经 N6-甲基腺苷 (m(6)A) 修饰的 Hsa_circ_0101308 通过海绵吸附 miR-224 影响宫颈癌的化疗耐药性

阅读:1

Abstract

BackgroundConsidering the significance of circRNA-miRNA network underlying cervical cancer (CC) development, this investigation was devised to explore whether and how 6-methyladinosinek (m(6)A)-adjusted hsa_circ_0101308/miR-224 axis participated in altering chemo-resistance in CC.MethodsForty-nine pairs of CC tissues and para-cancerous normal tissues were gathered, and CC cell lines, comprising HeLa, HeLa/DDP, HeLa/ADM and HeLa/TAX cell lines, were pre-prepared. Expressions of circRNAs, miRNAs and mRNAs were determined using quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and m(6)A-modification of hsa_circ_0101308 was verified based on methylated RNA immunoprecipitation sequencing (MeRIP-Seq) assay. Among CC cell lines, their chemo-resistance was evaluated through CCK8 assay, and their viability was assessed via MTT assay.ResultsHsa_circ_0101308 expression markedly dwindled, accompanied by notably elevated expression of miR-224, within CC tissues, when compared with para-cancerous normal tissues (P < 0.05). Hsa_circ_0101308 sponed miR-224 and suppressed its expression in HeLa cell line (P < 0.05), and either under-expressed m(6)A-adjusted hsa_circ_0101308 or over-expressed miR-224 strengthened viability of HeLa, HeLa/DDP, HeLa/ADM and HeLa/TAX cell lines (P < 0.05). Additionally, miR-224 targeted CADM1 and down-regulated its mRNA level (P < 0.05), which influenced p-PI3K/PI3K or p-Akt/Akt ratio (P < 0.05).ConclusionThe network combined by m(6)A-adjusted hsa_circ_0101308 and miR-224 interfered with chemo-resistance in CC via acting upon CADM1 and PI3K/AKT pathway, which was conducive to optimizing CC treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。